Tech and Science News
Apple, J&J to study if Apple Watch app leads to lower stroke risk
(Reuters) - Johnson & Johnson said on Tuesday it would partner with Apple Inc on a study to use an iPhone app and the Apple Watch to study how earlier detection of atrial fibrillation impacts stroke in people aged 65 or older.
Last year, Apple's Heart Study here found that the watch could accurately detect atrial fibrillation, the most common type of irregular heartbeat, according to a study that explored the role of wearable devices in identifying potential heart problems.
The new effort, called “Heartline,” is significant because J&J is one of the world’s largest medical device makers and pharmaceutical companies.
“What we bring is clinical study capability on a very large scale,” said Paul Stoffels, J&J’s chief scientific officer, who said the study aims to track 150,000 participants with long-term follow-ups over two years.
The study could also reach a different population than Apple’s original heart study, which included 400,000 participants but faced questions from medical experts because more than half of the people who signed up were under 40, a group already at low risk for atrial fibrillation.
J&J targeted the study at population with a higher risk. Paul Burton, vice president of medical affairs at the J&J subsidiary running the study, said 70% of patients experiencing the condition are over 65.
“What we’re trying to do here is definitively answer that question: If you take wearable technology and couple it with an app, can you reduce the risk of a stroke or death?” Burton said.
The J&J study will be open to the more than 40 million people enrolled in traditional Medicare plans, which cover people aged 65 and older as well as the disabled. Study participants will be randomly assigned to either use only an iPhone app or use the app in conjunction with a watch capable of taking an electrocardiogram, or ECG.
If patients who enroll are assigned to the arm of the study using the Apple Watch, they will be prompted to acquire one of the devices, which study officials said the participants can either purchase on their own for personal use for $49 or borrow free of charge for the study.
The latest Apple Watch model starts at list price of $399. Burton said J&J and Apple were sharing the cost of subsidizing the watches.
The study will also pay incentives to patients to participate. To take part, participants must share their Medicare claims data, which officials said was aimed at tracking the ultimate outcomes of using the app and watch.
(Corrects “afibrilation” to “atrial fibrillation” throughout)
Reporting by Ankur Banerjee in Bengaluru, Stephen Nellis in San Francisco and Caroline Humer in New York; Editing by Franklin Paul and Marguerita Choy
Our Standards:The Thomson Reuters Trust Principles.